Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models

Tumors often consist of hypoxic regions which are resistant to chemo- and radiotherapy. Evofosfamide (also known as TH-302), a 2-nitroimidazole triggered hypoxia-activated prodrug, preferentially releases the DNA cross-linker bromo-isophosphoramide mustard in hypoxic cells. The intracellular kinase...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Cancer Res
Autori principali: Sun, Jessica D, Ahluwalia, Dharmendra, Liu, Qian, Li, Wenwu, Wang, Yan, Meng, Fanying, Bhupathi, Deepthi, Matteucci, Mark D, Hart, Charles P
Natura: Artigo
Lingua:Inglês
Pubblicazione: e-Century Publishing Corporation 2015
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4548326/
https://ncbi.nlm.nih.gov/pubmed/26328245
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi